메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

3Shape Boosts Dental Lab Speed and Accuracy with AI-Powered Workflows

COPENHAGEN, Denmark, Feb. 19, 2026 -- At LMT LabDay today, 3Shape showcases its AI-powered and integrated workflows that help dental labs work faster, reduce errors, and handle more cases efficiently. A reliable bite setup in seconds Scans from intraoral scanners can sometimes include missing or inaccurate bite data. To save them time and eliminate their need for manual adjustment of missing jaw relationship data, 3Shape Dental System 2025 has introduced AI-bite alignment. The AI bite alignment tool analyzes dental arches in the scans and places them in a static occlusion
- 김갑성 기자
- 2026-02-19 21:07
Cambrex Announces Cornell Professor Song Lin as Recipient of the 2025 Snapdragon Prize for Innovation in Chemistry Technology

EAST RUTHERFORD, N.J., Feb. 19, 2026 -- Cambrex, a leading global contract development and manufacturing organization (CDMO) and Snapdragon Chemistry, a Cambrex company, are proud to announce that Dr. Song Lin, Tisch University Professor in chemistry and chemical biology at Cornell University's College of Arts and Sciences, has been awarded the 2025 Snapdragon Prize for Innovation in Chemistry Technology, which includes a $50,000 unrestricted fund for the Lin Lab. Professor Lin is being honored for his pioneering research in electrosynthetic chemistry, which has opened
- 김갑성 기자
- 2026-02-19 19:00
캠브렉스, 2025년 스냅드래곤 화학 기술 혁신상 수상자로 코넬대 송린 교수 선정

이스트러더퍼드, 뉴저지, 2026년 2월 19일 -- 글로벌 선도 의약품 위탁개발생산기업(contract development and manufacturing organization, CDMO)인 캠브렉스(Cambrex)와 캠브렉스 계열사인 스냅드래곤 케미스트리(Snapdragon Chemistry)가, 코넬대학교 예술과학대학의 화학 및 화학생물학과의 송린(Song Lin) 티시 석좌교수가 2025년 스냅드래곤 화학 기술 혁신상(2025 Snapdragon Prize for Innovation in Chemistry Technology) 수상자로 선정됐다고 발표했으며, 수상에는 린 연구실(Lin Lab)에 지원되는 미화 5만 달러의 무제한 연구 기금이 포함된다. 린 교수는 전기 합성 화학 분야의 선구적 연구로 수상의 영예를 안았으며, 그의 연구는 전기화학을 의약품 개발 및 제조에 활용하는 새로운 길을 열었다는 평가를 받는다. 린 교수의 연구실은 유기화학, 전기 합성, 촉매, 기술 개발 분야의 발전에 주력하고 있다. 특히 의약품 혁신에 핵심적인 카이랄 화합물을 포함한 복잡한 유기 분자의
- 김갑성 기자
- 2026-02-19 19:00
FDA, 치명적 약제내성 병원체 표적 신속 검사 2종을 혁신 의료기기로 지정

산타마리아, 캘리포니아 및 기프리, 프랑스 , 2026년 2월 19일 -- 엔지 바이오텍(NG Biotech)과 하디 다이애그노스틱스(Hardy Diagnostics)가 항생제 내성(Antimicrobial Resistance, AMR)에 대응하는 중대한 진전을 이룬 가운데 미국 식품의약국(Food and Drug Administration, FDA)에서 두 가지 신속 진단 분석법 NG-TEST®Candida auris와 NG-TEST®Acineto-5®을 혁신 의료기기로 지정했다고 2월 18일 발표했다. 이 지정은 생명을 위협하는 질환 및 중대한 미충족 의료 수요를 해결할 잠재력을 지닌 기술을 대상으로 하는 것이다. 두 검사는 모두 세계보건기구(World Health Organization, WHO)에서 최우선으로 분류한 병원체가 대상이다. 칸디다 아우리스(Candida auris)는 WHO 진균 우선순위 병원체 목록(Fungal Priority Pathogens List 2022)에 등재된 다제내성 효모로, 전 세계 병원 내 집단감염의 원인이 되고 있으며 검출이 어렵고 높은 사망률과 연관이 있다. 카바페
- 김갑성 기자
- 2026-02-19 10:31
A World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants

Japan's Ministry of Health, Labour and Welfare (MHLW) Approves PreemieFort® Enteral Solution as Prescription Medicine in the NICU DUARTE, Calif., Feb. 19, 2026 -- Prolacta Bioscience® today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved PreemieFort® Enteral Solution, a 100% human milk-based fortifier, as a prescription drug for very low birth weight infants, infants with congenital gastrointestinal disorders or congenital heart diseases, and those recovering from gastrointestinal surgery. This regulatory milestone was achieved in
- 김갑성 기자
- 2026-02-19 05:03
Lifespan Vision Ventures Co-Leads Sift Biosciences' $3.7M Pre-Seed Financing

NORWALK, Conn., Feb. 19, 2026 -- Lifespan Vision Ventures, an investment firm focused on therapeutics that improve human healthspan, today announced that it has co-led Sift Biosciences' oversubscribed $3.7 million Pre-Seed financing alongside Freeflow Ventures, with participation from Valuence Ventures, Eisai Innovation, SBI US Gateway Fund, and other early investors. Sift Biosciences is developing a peptide-based immunotherapy platform designed to harness pre-existing immune memory. The company's approach aims to generate more consistent immune engagement by activating memory
- 김갑성 기자
- 2026-02-19 01:00
Datasea Announces Foundational Research Breakthrough in Ultrasonic-Enhanced Nanoscale Precision Control

Establishing an Engineering-Level Core Technology for Next-Generation Semiconductor Manufacturing Applications BEIJING, Feb. 18, 2026 -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a Nevada-based technology company specializing in acoustic high-tech solutions and 5G+AI multimodal digitalization, today announced that it has achieved a foundational research breakthrough in its ultrasonic-enhanced nanoscale precision control technology, representing a step-change in the Company's technical architecture and underlying acoustic
- 김갑성 기자
- 2026-02-18 22:30
FDA Grants Breakthrough Device Designation to Two Rapid Tests Targeting Critical Drug-Resistant Pathogens

SANTA MARIA, Calif. and GUIPRY, France, Feb. 18, 2026 -- In a major step forward against Antimicrobial Resistance (AMR), NG Biotech, in partnership with Hardy Diagnostics, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designations to two rapid diagnostic assays: NG-TEST® Candida auris and NG-TEST® Acineto-5®. The designation recognizes technologies with the potential to address life-threatening conditions and significant unmet medical needs. Both tests target pathogens classified as critical priorities by the World
- 김갑성 기자
- 2026-02-18 20:43
Bioiberica Receives Frost & Sullivan's 2025 European New Product Innovation Award for Clinically Validated Native Type II Collagen

[ 메디채널 김갑성 기자 ] The recognition highlights Bioiberica's science-led innovation, clinical differentiation, and manufacturing excellence in the European innovative collagen market. SAN ANTONIO, Feb. 18, 2026 -- Frost & Sullivan is pleased to announce that Bioiberica has received the 2025 European New Product Innovation Recognition in the innovative collagen solutions industry for its outstanding achievements in clinical validation, ingredient differentiation, and evidence-based product development. This achievement reflects Bioiberica's consistent leadership in advancing scientific
- 김갑성 기자
- 2026-02-18 18:00
Chulalongkorn University Unveils AnthoRice™ Complex, A Breakthrough in Hair-Root Science

BANGKOK, Feb. 18, 2026 -- Chulalongkorn University and Mahidol University have entered a landmark technology-transfer collaboration to commercialize AnthoRice™ Complex, a Thai-developed hair-root care innovation derived from organic Riceberry rice, marking a significant step in translating academic research into real-world health and wellness applications. Developed by researchers from the Faculty of Pharmaceutical Sciences, Chulalongkorn University, AnthoRice™ Complex combines organic Riceberry rice extracts with StemAktiv® technology. The research has been validated in in
- 김갑성 기자
- 2026-02-18 10:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-03-02_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 02일 23시 00분